All In MedTech

Device Trial Radar · NCT02570113

The Peregrine Post-Market Study for the Treatment of Hypertension

A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Nov 2015

Primary completion

Feb 2019

Study completion Jul 2019

Sponsor

Lead sponsor
Ablative Solutions, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 7, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Ablative Solutions, Inc. Peregrine System Infusion Catheter is a catheter-based device which is intended to be used to ablate the afferent and efferent sympathetic nerves serving the kidneys. The catheter is inserted via the femoral artery, steered into the renal artery, and then delivers, by infusion from its distal end, a neurolytic agent. This targets the nerve bundles, which are in the adventitia - a sheath surrounding the artery. The aim is to reduce blood pressure in cases of hypertension, including seriously elevated blood pressure which does not respond to drug treatment. This study will evaluate the safety and performance of the device.

Conditions

  • Hypertension

Interventions

  • Peregrine System Infusion CatheterDevice

    The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure:Time frame: 1-month
  2. Change in 24-hour Mean Ambulatory Systolic Blood Pressure From Baseline to 6 MonthsTime frame: 6 months

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Na Homolce Hospital

    Prague, Czechia

  • Charite-Universitaetsmedizin Berlin

    Berlin, Germany

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.